Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885
Abstract
Seventeen patients were treated with echinomycin for metastatic renal cell carcinoma. Echinomycin is a bifunctional DNA intercalating agent with broad preclinical antitumor activity. It was given at 1200 mg/m2 by intravenous infusion over 30-60 min weekly for 4 weeks. The treatment was repeated every 6 weeks. There were no responses observed in the study. No life threatening or lethal toxicity was documented in 13 eligible patients. The median survival of these patients was 13.7 months. We conclude that echinomycin is not active against metastatic renal cell carcinoma at the dose and schedule tested.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical development of echinomycin was discontinued because it was not effective for patients with solid tumors refractory to all available treatments.
“However, clinical development was discontinued because echinomycin was not found to be effective for patients with solid tumors that were refractory to all available treatments.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [14]
Clinical studies have provided considerable safety data for echinomycin.
“Clinical studies have provided considerable safety data for echinomycin10-12, 14-18, 41-45”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [14]
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,607 · see citing works
Self-citationKarnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Rosenberg, S. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.180 · Cited by 390 · see citing works
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.
Elson, P. J., Witte, R. S., & Trump, D. L. (1988) · PubMed · Cited by 340 · see citing works
Self-citationHormonal therapy and chemotherapy of renal-cell carcinoma.
Harris, D. T. (1983) · PubMed · Cited by 171 · see citing works
Echinomycin: The first bifunctional intercalating agent in clinical trials
Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B. (1985) · Investigational New Drugs · doi:10.1007/bf00170766 · Cited by 61 · cited 1× · see citing works
“It is a cyclic peptide which is isolated from streptomyces echinatus and consists of two planar quinoxaline molecules connected by an octapeptide bridge [ 5 , 6]. It has been shown to inhibit the DNA and RNA syntheses and is active in the preclinical screening.”
BackgroundThe role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.
Figlin, R. A., Abi-Aad, A. S., Belldegrun, A. S., & deKernion, J. B. (1991) · PubMed · Cited by 30 · see citing works
Cytotoxic Activity of Echinomycin in a Human Tumor Cloning System
Lathan, B., & Hoff, D. D. V. (1984) · Cancer Drug Delivery · doi:10.1089/cdd.1984.1.191 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
Motzer, R. J., & Russo, P. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67889-5 · Cited by 595 · see citing works
Wang, Y., Liu, Y., Tang, F., Bernot, K. M., Schore, R., Marcucci, G., Caligiuri, M. A., Zheng, P., & Liu, Y. (2014) · Blood · doi:10.1182/blood-2013-12-544221 · Cited by 69 · see citing works
Alshaer, W., Zraikat, M. S., Amer, A., Nsairat, H., Lafi, Z., Alqudah, D. A., Qadi, E. A., Alsheleh, T., Odeh, F., Alkaraki, A., et al. (2019) · RSC Advances · doi:10.1039/c9ra05636j · Cited by 65 · see citing works
Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102278 · Cited by 44 · see citing works
A new antitumor agent: Methyl sulfonium perchlorate of echinomycin
Park, Y. S., Kim, Y. H., Kim, S. K., & Choi, S.-J. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00113-9 · Cited by 22 · see citing works
Satange, R., Chang, C.-C., Li, L., Lin, S., Neidle, S., & Hou, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad156 · Cited by 17 · see citing works
Quinomycin A reduces cyst progression in polycystic kidney disease
Radadiya, P. S., Thornton, M. M., Daniel, E. A., Idowu, J. Y., Wang, W., Magenheimer, B. S., Subramaniam, D., Tran, P. V., Calvet, J. P., Wallace, D. P., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002490r · Cited by 12 · see citing works
Echinomycin: A Journey of Challenges
Lafi, Z., Alshaer, W., Hatmal, M. M., Zihlif, M., Asha, N., Abdelnabi, H., & Awidi, A. (2023) · Jordan Journal of Pharmaceutical Sciences · doi:10.35516/jjps.v16i3.918 · Cited by 11 · see citing works
Johnson, D. H., Chang, A. Y. C., Ettinger, D. S., Kim, K. M., & Bonomi, P. (1998) · PubMed · Cited by 7 · see citing works
Self-citationSynthesis and biological evaluation of echinomycin analogues as potential colon cancer agent
Kojima, K., Konishi, H., Momosaki, K., Komatani, Y., Katsuyama, A., Nakagawa, K., Kanamitsu, K., Yakushiji, F., Fujiya, M., & Ichikawa, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-58196-3 · Cited by 5 · see citing works
Cheng, J., Jin, Y., Yang, S. H., & Suh, J. (2013) · Journal of the Korean Society for Applied Biological Chemistry · doi:10.1007/s13765-012-2227-x · Cited by 4 · see citing works
The bisintercalator family of nonribosomal peptides: structural diversity and biosynthetic mechanism
Shi, X. (2025) · Natural Product Reports · doi:10.1039/d5np00003c · Cited by 2 · see citing works
Chemotherapy for Metastatic Renal Cell Carcinoma (RCC)
Ruiz, J. A., Raftopoulos, H., & Petrylak, D. P. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-229-6_18 · Cited by 2 · see citing works
Treatment of Graft-versus-Host Disease by Echinomycin in a New Humanized Mouse ModelPreprint
Liu, Y., Bailey, C. M., Lazarski, C. A., Wong, C.-S., Zheng, P., Liu, Y., & Wang, Y. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/108951 · Cited by 2 · see citing works
Combination Therapy for Treatment of Advanced Renal Cell Carcinoma
Atzpodien, J., Janßen, J., Buer, J., Sel, S., & Oevermann, K. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-229-6_21 · Cited by 1 · see citing works
Atzpodien, J., Buer, J., & Probst‐Kepper, M. (1998) · Springer eBooks · doi:10.1007/978-3-662-10493-4_43
- Authors
- Chang, A. Y., Tu, Z. N., Bryan, G. T., Kirkwood, J. M., Oken, M. M., & Trump, D. L.
- Affiliations
- University of Rochester Medicine (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Wisconsin–Madison (US)
- University of Pittsburgh (US)
- Venue
- Investigational New Drugs
- Published
- 1994-06
- Volume
- 12
- Issue
- 2
- Pages
- 151-153
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W1972694699
- Cited by
- 16
- References
- 7
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2014: 1 · 2013: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-23318, CA-18653, U10CA023318, U10CA021115, CA 21115)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- echinomycin, renal cell carcinoma, metastatic renal cell carcinoma, DNA intercalators, cancer chemotherapy, treatment toxicity, survival
- MeSH terms
- Aged, Carcinoma, Renal Cell, Echinomycin, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Statistics as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
